drugset

drugset / Trial / NCT07531745

ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

NCT07531745 ↗

Phase 1/2 Recruiting 32 enrolled Ionis Pharmaceuticals, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).

Timeline

Start: 2026-05-21
Primary completion: 2030-12
Completion: 2030-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ION337	Unknown	—	Intrathecal

Indications